Alan P Venook Md On Integrating Immunotherapy Into Existing Treatment Regimens For Hcc Patients Obroncology Mp3 & Mp4 Download

1:37

alan p. venook, md, on integrating immunotherapy into existing treatment regimens for crc patients

1:05

alan p. venook, md, on integrating immunotherapy into treatment regimens for gastric cancer patients

1:57

recent immunotherapy advances in hcc management

0:52

alan p. venook, md, on identifying subgroups of hcc patients that are likely to respond to therapy

0:25

alan venook, md on integrating regorafenib and trifluridine into the 2nd line treatment of mcrc

1:44

alan venook, md, considers how immunotherapy is being integrated into crc treatment algorithms

1:18

alan venook, md, on the latest in identifying valid biomarkers in the treatment of hcc

1:47

alan venook, md discusses development of immunotherapies for non msi-high crc patients

1:03:32

immunotherapy converts locally advanced hepatocellular carcinoma into resectable disease

1:57

advancing translational work in a rare cancer: lessons from fibrolamellar carcinoma

2:16

alan venook, md, describes the potential practice changing results of the keynote-177 study

1:17

alan p. venook, md, discusses which molecular tests to order for a newly diagnosed crc patient

1:33:36

antibody therapy in all: how and why to integrate antibody-based treatment into patient management

1:21

alan p. venook, md, provides his perspective on using tas-102 and regorafenib in crc patients

2:25

keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma

7:41

alan p. venook, md, on integrating immunotherapy into existing treatment regimens for hcc patients

Download video MP4

Download video MP3

Similar videos

alan p. venook, md, on integrating immunotherapy into existing treatment regimens for crc patients

alan p. venook, md, on integrating immunotherapy into treatment regimens for gastric cancer patients

recent immunotherapy advances in hcc management

alan p. venook, md, on identifying subgroups of hcc patients that are likely to respond to therapy

alan venook, md on integrating regorafenib and trifluridine into the 2nd line treatment of mcrc

alan venook, md, considers how immunotherapy is being integrated into crc treatment algorithms

alan venook, md, on the latest in identifying valid biomarkers in the treatment of hcc

alan venook, md discusses development of immunotherapies for non msi-high crc patients

immunotherapy converts locally advanced hepatocellular carcinoma into resectable disease

dr. finn on recent advances in the treatment of liver cancer

dr. venook on immunotherapy potential in colorectal cancer

choosing the best treatment regimen in advanced hepatocellular carcinoma

advancing translational work in a rare cancer: lessons from fibrolamellar carcinoma

alan venook, md, describes the potential practice changing results of the keynote-177 study

alan p. venook, md, discusses which molecular tests to order for a newly diagnosed crc patient

antibody therapy in all: how and why to integrate antibody-based treatment into patient management

alan p. venook, md, provides his perspective on using tas-102 and regorafenib in crc patients

keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma

perioperative approaches to hcc management